Genocea Biosciences Inc. [NASDAQ: GNCA] jumped around 0.62 points on Wednesday, while shares priced at $3.07 at the close of the session, up 25.31%. The company report on January 5, 2021 that Genocea to Present at the H.C. Wainwright Virtual BioConnect Conference.
Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that Chip Clark, president and chief executive officer, will present a corporate overview at the H.C. Wainwright Virtual BioConnect Conference being held from January 11 – 14, 2021. A webcast of the on-demand presentation will be available on the investor section of the Genocea website at http://ir.genocea.com, beginning on Monday, January 11, 2021.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Following the conclusion of the conference, the presentation will remain archived on the Genocea website for approximately 90 days.
Genocea Biosciences Inc. stock is now 26.86% up from its year-to-date (YTD) trading value. GNCA Stock saw the intraday high of $3.50 and lowest of $2.41 per share. The company’s 52-week high price is 5.75, which means current price is +31.20% above from all time high which was touched on 01/13/21.
Compared to the average trading volume of 355.22K shares, GNCA reached a trading volume of 3072835 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Genocea Biosciences Inc. [GNCA]?
SVB Leerink have made an estimate for Genocea Biosciences Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on November 15, 2019. While these analysts kept the previous recommendation, Stifel raised their target price to Buy. The new note on the price target was released on July 08, 2019, representing the official price target for Genocea Biosciences Inc. stock.
The Average True Range (ATR) for Genocea Biosciences Inc. is set at 0.25, with the Price to Sales ratio for GNCA stock in the period of the last 12 months amounting to 116.51. The Price to Book ratio for the last quarter was 8.53, with the Price to Cash per share for the same quarter was set at 1.65.
How has GNCA stock performed recently?
Genocea Biosciences Inc. [GNCA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 25.31. With this latest performance, GNCA shares gained by 40.83% in over the last four-week period, additionally plugging by 59.07% over the last 6 months – not to mention a rise of 29.54% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for GNCA stock in for the last two-week period is set at 67.26, with the RSI for the last a single of trading hit 71.28, and the three-weeks RSI is set at 64.28 for Genocea Biosciences Inc. [GNCA]. The present Moving Average for the last 50 days of trading for this stock 2.27, while it was recorded at 2.57 for the last single week of trading, and 2.40 for the last 200 days.
Genocea Biosciences Inc. [GNCA]: Deeper insight into the fundamentals
Return on Total Capital for GNCA is now -116.18, given the latest momentum, and Return on Invested Capital for the company is -128.24. Return on Equity for this stock declined to -240.60, with Return on Assets sitting at -93.04. When it comes to the capital structure of this company, Genocea Biosciences Inc. [GNCA] has a Total Debt to Total Equity ratio set at 79.54. Additionally, GNCA Total Debt to Total Capital is recorded at 44.30, with Total Debt to Total Assets ending up at 37.86. Long-Term Debt to Equity for the company is recorded at 77.24, with the Long-Term Debt to Total Capital now at 41.82.
Reflecting on the efficiency of the workforce at the company, Genocea Biosciences Inc. [GNCA] managed to generate an average of -$660,169 per employee.Genocea Biosciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.80 and a Current Ratio set at 3.80.
Earnings analysis for Genocea Biosciences Inc. [GNCA]
With the latest financial reports released by the company, Genocea Biosciences Inc. posted -0.34/share EPS, while the average EPS was predicted by analysts to be reported at -0.39/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 12.80%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for GNCA.
Insider trade positions for Genocea Biosciences Inc. [GNCA]
There are presently around $85 million, or 54.70% of GNCA stock, in the hands of institutional investors. The top three institutional holders of GNCA stocks are: NEA MANAGEMENT COMPANY, LLC with ownership of 10,376,936, which is approximately 43.612% of the company’s market cap and around 6.98% of the total institutional ownership; AVORO CAPITAL ADVISORS LLC, holding 5,084,184 shares of the stock with an approximate value of $15.61 million in GNCA stocks shares; and BVF INC/IL, currently with $12.32 million in GNCA stock with ownership of nearly 98.792% of the company’s market capitalization.
Positions in Genocea Biosciences Inc. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 22 institutional holders increased their position in Genocea Biosciences Inc. [NASDAQ:GNCA] by around 15,420,392 shares. Additionally, 19 investors decreased positions by around 1,192,956 shares, while 4 investors held positions by with 11,155,226 shares. The mentioned changes placed institutional holdings at 27,768,574 shares, according to the latest SEC report filing. GNCA stock had 11 new institutional investments in for a total of 7,057,685 shares, while 8 institutional investors sold positions of 732,899 shares during the same period.